

CITATION REPORT

List of articles citing

Phosphodiesterase type 5 inhibitors and kidney disease

DOI: 10.1007/s11255-015-1071-4

International Urology and Nephrology, 2015, 47, 1521-8.

Source: <https://exaly.com/paper-pdf/62495920/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	The next generation of therapeutics for chronic kidney disease. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 568-88	64.1	140
26	Coronary Heart Disease, Diabetes, and Sexuality in Men. <i>Journal of Sexual Medicine</i> , 2016 , 13, 887-904	1.1	28
25	The role of cGMP and its signaling pathways in kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F671-F681	4.3	17
24	Emerging therapeutics for the treatment of diabetic nephropathy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 4394-4402	2.9	26
23	Targeting inflammation in diabetic kidney disease: early clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2016 , 25, 1045-58	5.9	52
22	The Graham Jackson Memorial Lecture ISSM 2016-"The Man Who Knew Too Much": Time to Recognize Erectile Dysfunction and Low Testosterone as Independent Risk Factors for Cardiovascular Disease. <i>Sexual Medicine Reviews</i> , 2017 , 5, 256-265	5.6	11
21	Genetics of NO Deficiency. <i>American Journal of Cardiology</i> , 2017 , 120, S80-S88	3	8
20	Kidney dysfunction in patients with pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017 , 7, 38-54	2.7	30
19	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 183-192	5.5	19
18	Anti-fibrotic treatments: A review of clinical evidence. <i>Matrix Biology</i> , 2018 , 68-69, 333-354	11.4	35
17	Erectile dysfunction and testosterone deficiency as cardiovascular risk factors?. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13054	2.9	6
16	The mechanism of attenuation of epithelial-mesenchymal transition by a phosphodiesterase 5 inhibitor via renal klotho expression. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018 , 45, 269-277	3	3
15	Renoprotective effect of local sildenafil administration in renal ischaemia-reperfusion injury: A randomised controlled canine study. <i>Arab Journal of Urology Arab Association of Urology</i> , 2019 , 17, 150-159	1.7	8
14	Therapeutic options for chronic kidney disease-associated pulmonary hypertension. <i>Current Opinion in Nephrology and Hypertension</i> , 2020 , 29, 497-507	3.5	1
13	Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
12	Phosphodiesterase-5 inhibitors ameliorate structural kidney damage in a rat model of contrast-induced nephropathy. <i>Food and Chemical Toxicology</i> , 2020 , 143, 111535	4.7	13
11	Pulmonary hypertension in end-stage renal disease. <i>Respiratory Medicine</i> , 2020 , 164, 105905	4.6	0

10	Reno-protective effects of Phosphodiesterase 5 inhibitors. <i>Clinical and Experimental Nephrology</i> , 2021 , 25, 585-597	2.5	3
9	Local cyclic adenosine monophosphate signalling cascades-Roles and targets in chronic kidney disease. <i>Acta Physiologica</i> , 2021 , 232, e13641	5.6	2
8	Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy. <i>Current Medicinal Chemistry</i> , 2021 , 28, 1003-1024	4.3	3
7	Impaired pulmonary vasomotor control in exercising swine with multiple comorbidities. <i>Basic Research in Cardiology</i> , 2021 , 116, 51	11.8	1
6	New progress in drugs treatment of diabetic kidney disease. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 141, 111918	7.5	3
5	Phosphodiesterase-5 inhibitor sildenafil attenuates kidney injury induced by Bothrops alternatus snake venom. <i>Toxicon</i> , 2021 , 202, 46-52	2.8	0
4	Redox Switches Controlling Nitric Oxide Signaling in the Resistance Vasculature and Implications for Blood Pressure Regulation: Mid-Career Award for Research Excellence 2020. <i>Hypertension</i> , 2021 , 78, 912-926	8.5	5
3	Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?. <i>World Journal of Men's Health</i> , 2020 , 38, 271-284	6.8	6
2	Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. <i>Meditinskiy Sovet</i> , 2019 , 192-202	0.4	
1	The Phosphodiesterase-5 Inhibitors and Prostate Cancer [What We Rely Know About It?. <i>Serbian Journal of Experimental and Clinical Research</i> , 2019 ,	0.3	